Tight Blood-Glucose Control without Early Parenteral Nutrition in the ICU.
Journal
The New England journal of medicine
ISSN: 1533-4406
Titre abrégé: N Engl J Med
Pays: United States
ID NLM: 0255562
Informations de publication
Date de publication:
28 Sep 2023
28 Sep 2023
Historique:
medline:
28
9
2023
pubmed:
27
9
2023
entrez:
27
9
2023
Statut:
ppublish
Résumé
Randomized, controlled trials have shown both benefit and harm from tight blood-glucose control in patients in the intensive care unit (ICU). Variation in the use of early parenteral nutrition and in insulin-induced severe hypoglycemia might explain this inconsistency. We randomly assigned patients, on ICU admission, to liberal glucose control (insulin initiated only when the blood-glucose level was >215 mg per deciliter [>11.9 mmol per liter]) or to tight glucose control (blood-glucose level targeted with the use of the LOGIC-Insulin algorithm at 80 to 110 mg per deciliter [4.4 to 6.1 mmol per liter]); parenteral nutrition was withheld in both groups for 1 week. Protocol adherence was determined according to glucose metrics. The primary outcome was the length of time that ICU care was needed, calculated on the basis of time to discharge alive from the ICU, with death accounted for as a competing risk; 90-day mortality was the safety outcome. Of 9230 patients who underwent randomization, 4622 were assigned to liberal glucose control and 4608 to tight glucose control. The median morning blood-glucose level was 140 mg per deciliter (interquartile range, 122 to 161) with liberal glucose control and 107 mg per deciliter (interquartile range, 98 to 117) with tight glucose control. Severe hypoglycemia occurred in 31 patients (0.7%) in the liberal-control group and 47 patients (1.0%) in the tight-control group. The length of time that ICU care was needed was similar in the two groups (hazard ratio for earlier discharge alive with tight glucose control, 1.00; 95% confidence interval, 0.96 to 1.04; P = 0.94). Mortality at 90 days was also similar (10.1% with liberal glucose control and 10.5% with tight glucose control, P = 0.51). Analyses of eight prespecified secondary outcomes suggested that the incidence of new infections, the duration of respiratory and hemodynamic support, the time to discharge alive from the hospital, and mortality in the ICU and hospital were similar in the two groups, whereas severe acute kidney injury and cholestatic liver dysfunction appeared less prevalent with tight glucose control. In critically ill patients who were not receiving early parenteral nutrition, tight glucose control did not affect the length of time that ICU care was needed or mortality. (Funded by the Research Foundation-Flanders and others; TGC-Fast ClinicalTrials.gov number, NCT03665207.).
Sections du résumé
BACKGROUND
BACKGROUND
Randomized, controlled trials have shown both benefit and harm from tight blood-glucose control in patients in the intensive care unit (ICU). Variation in the use of early parenteral nutrition and in insulin-induced severe hypoglycemia might explain this inconsistency.
METHODS
METHODS
We randomly assigned patients, on ICU admission, to liberal glucose control (insulin initiated only when the blood-glucose level was >215 mg per deciliter [>11.9 mmol per liter]) or to tight glucose control (blood-glucose level targeted with the use of the LOGIC-Insulin algorithm at 80 to 110 mg per deciliter [4.4 to 6.1 mmol per liter]); parenteral nutrition was withheld in both groups for 1 week. Protocol adherence was determined according to glucose metrics. The primary outcome was the length of time that ICU care was needed, calculated on the basis of time to discharge alive from the ICU, with death accounted for as a competing risk; 90-day mortality was the safety outcome.
RESULTS
RESULTS
Of 9230 patients who underwent randomization, 4622 were assigned to liberal glucose control and 4608 to tight glucose control. The median morning blood-glucose level was 140 mg per deciliter (interquartile range, 122 to 161) with liberal glucose control and 107 mg per deciliter (interquartile range, 98 to 117) with tight glucose control. Severe hypoglycemia occurred in 31 patients (0.7%) in the liberal-control group and 47 patients (1.0%) in the tight-control group. The length of time that ICU care was needed was similar in the two groups (hazard ratio for earlier discharge alive with tight glucose control, 1.00; 95% confidence interval, 0.96 to 1.04; P = 0.94). Mortality at 90 days was also similar (10.1% with liberal glucose control and 10.5% with tight glucose control, P = 0.51). Analyses of eight prespecified secondary outcomes suggested that the incidence of new infections, the duration of respiratory and hemodynamic support, the time to discharge alive from the hospital, and mortality in the ICU and hospital were similar in the two groups, whereas severe acute kidney injury and cholestatic liver dysfunction appeared less prevalent with tight glucose control.
CONCLUSIONS
CONCLUSIONS
In critically ill patients who were not receiving early parenteral nutrition, tight glucose control did not affect the length of time that ICU care was needed or mortality. (Funded by the Research Foundation-Flanders and others; TGC-Fast ClinicalTrials.gov number, NCT03665207.).
Identifiants
pubmed: 37754283
doi: 10.1056/NEJMoa2304855
doi:
Substances chimiques
Blood Glucose
0
Glucose
IY9XDZ35W2
Insulin
0
Banques de données
ClinicalTrials.gov
['NCT03665207']
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1180-1190Subventions
Organisme : Universitaire Ziekenhuizen Leuven, KU Leuven
ID : Anonymous Donation from a Dutch Family to dr. Van
Organisme : Fonds Wetenschappelijk Onderzoek
ID : Senior Clinical Investigator fellowship to Drs Cas
Organisme : Fonds Wetenschappelijk Onderzoek
ID : TBM T003617N to Drs. Van den Berghe, Gunst and Ben
Organisme : Vlaamse Overheid
ID : Methusalem grant METH14/06 via KU Leuven to Dr. Va
Organisme : H2020 European Research Council
ID : AdvG-2017-785809 to dr. Van den Berghe
Organisme : Universitaire Ziekenhuizen Leuven, KU Leuven
ID : Doctoral and post-doctoral fellowships to drs. De
Organisme : Universitair Ziekenhuis Gent
ID : Type 2 project Fund for innovation and clinical re
Investigateurs
Jan Gunst
(J)
Yves Debaveye
(Y)
Fabian Güiza
(F)
Jasperina Dubois
(J)
Astrid De Bruyn
(A)
Dieter Dauwe
(D)
Erwin De Troy
(E)
Michael P Casaer
(MP)
Greet De Vlieger
(G)
Renata Haghedooren
(R)
Bart Jacobs
(B)
Geert Meyfroidt
(G)
Catherine Ingels
(C)
Jan Muller
(J)
Dirk Vlasselaers
(D)
Lars Desmet
(L)
Liese Mebis
(L)
Pieter J Wouters
(PJ)
Björn Stessel
(B)
Laurien Geebelen
(L)
Jeroen Vandenbrande
(J)
Michiel Brands
(M)
Ine Gruyters
(I)
Ester Geerts
(E)
Ilse De Pauw
(I)
Joris Vermassen
(J)
Harlinde Peperstraete
(H)
Eric Hoste
(E)
Jan J De Waele
(JJ)
Ingrid Herck
(I)
Pieter Depuydt
(P)
Alexander Wilmer
(A)
Greet Hermans
(G)
Dominique D Benoit
(DD)
Greet Van den Berghe
(G)
Philippe Huynen
(P)
Colin Coucke
(C)
Alexander Dehouwer
(A)
Simon De Ridder
(S)
Melanie Dekeyser
(M)
Annelies Dionys
(A)
Maarten Hendrickx
(M)
Mieke Maeckelberghe
(M)
Jolien Schildermans
(J)
Walter Staelens
(W)
Alexandra Hendrickx
(A)
Heidi Utens
(H)
Hanna Van Cleemput
(H)
Sylvia Van Hulle
(S)
Katleen Witpas
(K)
Philippe Meersseman
(P)
Joost Wauters
(J)
Marijke Peetermans
(M)
Ina Callebaut
(I)
Greetje Coninckx
(G)
Philippe Jamaer
(P)
Marijke Nulens
(M)
Vital Swinnen
(V)
Jeroen Herbots
(J)
Liesbeth Heremans
(L)
Johan Hermans
(J)
Noor Berends
(N)
Michiel Van Tornout
(M)
Dirk Vranken
(D)
Hassanin Jalil
(H)
Jan Fierens
(J)
Patrick Druwé
(P)
Sandra Oeyen
(S)
Liesbet De Bus
(L)
Kirsten Colpaert
(K)
Lander Vanhulle
(L)
Carl Roosens
(C)
Johan Decruyenaere
(J)
Klaas Vanderbiest
(K)
Wim Vandenberghe
(W)
Lien Van Laethem
(L)
Hannah Schaubroeck
(H)
Julie Dillemans
(J)
Thomas Couck
(T)
Daisy Vermeiren
(D)
Jolien Van Hecke
(J)
Anouska De Smeytere
(A)
Lesley Decoster
(L)
Bram Gadeyne
(B)
Veerle Brams
(V)
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2023 Massachusetts Medical Society.